IMCL
Imclone Systems, Inc
Biopharmaceutical company focused on oncology research and the development of the cancer drug Erbitux; acquired by Eli Lilly in 2008
CUSIP: 45245W109HealthcareUS1 holder
Imclone Systems, Inc
Biopharmaceutical company focused on oncology research and the development of the cancer drug Erbitux; acquired by Eli Lilly in 2008
No Schedule 13D or 13G filings recorded.